Search Results - David R. Spigel

Refine Results
  1. 1
    Advances in molecular‐based personalized non‐small‐cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance

    Advances in molecular‐based personalized non‐small‐cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance by Robert M. Jotte, David R. Spigel

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches

    Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches by David R. Spigel, Mark A. Socinski

    Published 2013
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer

    The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer by Leora Horn, Martin Reck, David R. Spigel

    Published 2016
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study

    Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study by John D. Hainsworth, David R. Spigel, Sharlene Litchy, F. Anthony Greco

    Published 2006
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology

    Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology by F. Anthony Greco, Wayne J. Lennington, David R. Spigel, John D. Hainsworth

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network

    Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network by John D. Hainsworth, David R. Spigel, C. Farley, Dana S. Thompson, Dianna Shipley, F. Anthony Greco

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib

    Treatment of Metastatic Renal Cell Carcinoma With a Combination of Bevacizumab and Erlotinib by John D. Hainsworth, Jeffrey A. Sosman, David R. Spigel, Donna L. Edwards, Cara Baughman, Anthony Greco

    Published 2005
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts

    Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts by Martin Reck, Fabrice Barlési, Lucio Crinò, Claudia I. Henschke, Dolores Isla, Susanne Stiebeler, David R. Spigel

    Published 2011
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  9. 9
    Molecular Profiling in Unknown Primary Cancer: Accuracy of Tissue of Origin Prediction

    Molecular Profiling in Unknown Primary Cancer: Accuracy of Tissue of Origin Prediction by F. Anthony Greco, David R. Spigel, Denise A. Yardley, Mark G. Erlander, Xiaojun Ma, John D. Hainsworth

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute

    Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the... by John D. Hainsworth, Mark S. Rubin, David R. Spigel, Ralph V. Boccia, Samuel Raby, Raven Quinn, F. Anthony Greco

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association With Atopic History

    High Incidence of Cetuximab-Related Infusion Reactions in Tennessee and North Carolina and the Association With Atopic History by Bert H. O’Neil, Robert M. Allen, David R. Spigel, Thomas E. Stinchcombe, Dominic T. Moore, Jordan Berlin, Richard M. Goldberg

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site

    Paclitaxel/Carboplatin plus Bevacizumab/Erlotinib in the First-Line Treatment of Patients with Carcinoma of Unknown Primary Site by John D. Hainsworth, David R. Spigel, Dana S. Thompson, Patrick Murphy, Cassie M. Lane, David Waterhouse, Yuval Naot, F. Anthony Greco

    Published 2009
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer

    Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer by John D. Hainsworth, David R. Spigel, C. Farley, Dianna Shipley, James D. Bearden, Jitendra G. Gandhi, Gerry Ann Houston, F. Anthony Greco

    Published 2007
    Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057

    PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057 by Richard J. Gralla, David R. Spigel, Bryan Bennett, Fiona Taylor, John R. Penrod, Michael DeRosa, Homa Dastani, Lucinda Orsini, Clarissa Mathias, Martin Reck

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    P2.46 (also presented as PD1.01): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057

    P2.46 (also presented as PD1.01): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057 by Richard J. Gralla, David R. Spigel, Bryan Bennett, Fiona Taylor, John R. Penrod, Michael DeRosa, Homa Dastani, Lucinda Orsini, Clarissa Mathias, Martin Reck

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer

    Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer by David R. Spigel, F. Anthony Greco, John D. Zubkus, Patrick Murphy, Ruben A. Saez, C. Farley, Denise A. Yardley, Howard A. Burris, John D. Hainsworth

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial

    Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial by David R. Spigel, P. Townley, David Waterhouse, Fang Ting Liang, İbrahim Adıgüzel, Jane E. Huang, David A. Karlin, Leonardo Faoro, Frank A. Scappaticci, Mark A. Socinski

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung

    Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung by David R. Spigel, Martin J. Edelman, Kenneth J. O’Byrne, Luis Paz‐Ares, Simonetta Mocci, See Phan, David S. Shames, Dustin Smith, Wei Yu, Virginia Paton, Tony Mok

    Published 2017
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort

    Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohor... by Howard A. Burris, Suzanne J. Bakewell, Johanna C. Bendell, Jeffrey R. Infante, Suzanne F. Jones, David R. Spigel, Glen J. Weiss, Ramesh K. Ramanathan, Angela Ogden, Daniel D. Von Hoff

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

    Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study by John D. Hainsworth, Funda Meric‐Bernstam, Charles Swanton, Herbert I. Hurwitz, David R. Spigel, Christopher J. Sweeney, Howard A. Burris, Ron Bose, Bongin Yoo, Alisha Stein, Mary Beattie, Razelle Kurzrock

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: